Therapeutics
Examples of evidence include:
Related pages
- Diabetes control and complications trial
- CALM study
- UK Prospective Diabetes Study
- Orlistat in obese type II diabetics
- Heart Outcomes Prevention Evaluation Study
- MRC/BHF Heart Protection Study ( HPS )
- Proactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study
- EMPA - REG trial - empagliflozin in type 2 diabetes patients with high cardiovascular risk (EMPAREG)
- CANVAS Program - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial
- SUSTAIN-6 - subcutaneous semaglutide and cardiovascular outcomes in type 2 Diabetes
- DECLARE - TIMI 58 - dapagliflozin and cardiovascular outcomes in type 2 diabetes
- CREDENCE - canagliflozin and renal outcomes in type 2 diabetes (diabetic) and nephropathy
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF)
- Diabetes Remission Clinical Trial (DiRECT) using diet in diabetes
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page